Phanes Biotech | LinkedIn (original) (raw)
Biotechnology Research
Malvern, Pennsylvania 303 followers
" Shifting the balance from NeuroDegeneration to NeuroRegeenration"
About us
Phanes Biotech is an early-stage drug development biotechnology company focused on developing molecules to prevent, inhibit, and reverse neurodegenerative diseases and developmental disabilities by neural regeneration, and in the case of tauopathies by tau immunotherapy.
Industry
Biotechnology Research
Company size
2-10 employees
Headquarters
Malvern, Pennsylvania
Type
Privately Held
Founded
2020
Specialties
Alzheimer's Disease, Neurodegenerative Disorders, Macular degeneration, Dementia, Neuroregeneration, Amyloid, and Tau
Locations
Employees at Phanes Biotech
Updates
- Alzheimer’s disease (AD) contributes to 60–70% of cases of dementia. An estimated 5.9 million Americans live with the disease today, while the global total is about 44 million; these numbers are likely to reach 13.8 million in the U.S. and 131.5 million worldwide by 2050. ⚕️ Phanes Biotech - Impacting Lives Through Revolutionary Treatment For Neurodegenerative Disorders. Learn more about what we do here: phanesbiotech.com #alzheimers #dementia #alzheimersawareness #healthcare #clinicalresearch #PhanesBiotech
- 🌟 Pioneering a New Era in Alzheimer’s Detection! 🌟 We’re thrilled to announce a groundbreaking partnership between Phanes Biotech and Veravas to redefine Alzheimer’s disease diagnostics. Together, we’re co-developing a next-generation blood-based assay powered by Phanes Biotech’s proprietary tau monoclonal antibody. This innovative tool will enable unprecedented accuracy in detecting tau pathology, a critical biomarker in Alzheimer’s disease. This is more than an advancement in diagnostics—it’s a breakthrough that could profoundly change patient care. By detecting Alzheimer’s not only in symptomatic patients but also in those at risk, we’re opening doors to early intervention and transforming possibilities for millions affected by this disease. This collaboration reflects our unwavering commitment to advancing science and improving lives, made possible by the support of our partners and investors who share our mission. Together, we’re driving innovation forward and creating solutions that will reshape the future of Alzheimer’s care. For the full announcement, click here: https://lnkd.in/gG9q3n_VLet’s continue to push the boundaries of what’s possible in healthcare
#PhanesBiotech #Veravas #DiagnosticsBreakthrough #HealthcareTransformation #NeurodegenerativeDisease #BiotechForGood #AdvancingScience #PatientCare
VERAVAS, Inc. And Phanes Biotech Partner To Develop Blood-Based Alzheimer’s Diagnostic Test Learn more & get our take 👇https://lnkd.in/gXuERp3R“Scientific discovery and therapeutic development in Alzheimer’s disease are surging, offering clinicians viable new opportunities to intervene early, potentially slow Alzheimer’s disease progression, and improve quality of life for patients.” — Khalid Iqbal, Ph.D., Chief Scientific Officer at Phanes Biotech “Our technology has the potential to eliminate the uncertainties and accessibility hurdles of current Alzheimer’s disease diagnostics for the benefit of clinicians diagnosing and treating AD, their patients, and researchers conducting clinical trials.” — Joshua Soldo, Chief Scientific Officer at Veravas#SoHCNews
Veravas and Phanes Biotech Partner to Develop Blood-Based Alzheimer’s Diagnostic Test https://sliceofhealthcare.com - 🌟 Pioneering a New Era in Alzheimer’s Detection! 🌟 We’re thrilled to announce a groundbreaking partnership between Phanes Biotech and Veravas to redefine Alzheimer’s disease diagnostics. Together, we’re co-developing a next-generation blood-based assay powered by Phanes Biotech’s proprietary tau monoclonal antibody. This innovative tool will enable unprecedented accuracy in detecting tau pathology, a critical biomarker in Alzheimer’s disease. This is more than an advancement in diagnostics—it’s a breakthrough that could profoundly change patient care. By detecting Alzheimer’s not only in symptomatic patients but also in those at risk, we’re opening doors to early intervention and transforming possibilities for millions affected by this disease. This collaboration reflects our unwavering commitment to advancing science and improving lives, made possible by the support of our partners and investors who share our mission. Together, we’re driving innovation forward and creating solutions that will reshape the future of Alzheimer’s care. For the full announcement, click here: https://lnkd.in/gG9q3n_VLet’s continue to push the boundaries of what’s possible in healthcare
Chief Communications Officer, STEM NOLA | STEM Global Action • Board Chair, Alzheimer's Association Louisiana Chapter [22.3K+ micro-influencers]
2mo
In his article for Healio, Robert Herpen, MA, reports on a new partnership between a clinical diagnostics company, VERAVAS, Inc., and a biotech firm, Phanes Biotech, to develop a blood test for Alzheimer’s disease. This test will focus on detecting tau pathology, which is a key indicator of Alzheimer’s. The companies plan to use Veravas’ VeraBIND technology and Phanes’ special antibody to find changes in tau proteins in the brain. This blood test aims to make diagnosing Alzheimer’s disease faster and easier, by detecting tau protein abnormalities linked to the disease. Tau buildup in the brain is a major sign of Alzheimer’s and is usually detected through expensive and slow tests like tau PET imaging. By creating a blood test, the companies hope to make diagnosing Alzheimer’s quicker, more affordable, and more accessible. Early detection could lead to better treatments, potentially slowing the progression of the disease and improving patient care. The partnership is part of the growing effort to find practical ways to diagnose Alzheimer’s sooner, helping scientists and doctors better manage the disease.#Alzheimers #BloodTest #TauPathology #InnovativeDiagnostics #AlzheimersResearch #TrustScience #ENDALZ #AlzheimersAwareness https://lnkd.in/gzH873ay
Blood-based tau pathology test for Alzheimer’s disease in development healio.com - Caregivers for individuals with dementia face unique challenges. When patients exhibit additional complexities such as depression, behavioral disturbances, or low functional status, the caregiver's burden intensifies significantly. Research indicates a direct correlation between these factors and increased healthcare utilization among caregivers. This includes higher rates of emergency department visits, hospitalizations, and medication use. It is crucial to recognize the profound impact these challenges have on caregiver health and well-being. Get in touch with us: https://buff.ly/3DbmnMz #alzheimers #dementia
- P021 promotes and rescues neural formation (neurogenesis) and the brain’s ability to rewire (neuronal plasticity) by competitively enhancing the activity of brain-derived neurotrophic factor (BDNF), leading to both prevention of the destruction of some nerve cells and regeneration and repair of destroyed nerve cells. Get in touch with us: https://buff.ly/3DbmnMz #alzheimers #dementia
- By ensuring that all rooms and outdoor areas are well-lit, you can create a safer and more comfortable environment for your loved one. Consider using soft, warm light bulbs to minimize shadows and glare, and install nightlights for added safety. Remember, good lighting isn't just about visibility; it's about creating a soothing and familiar atmosphere. Get in touch with us: https://buff.ly/3DbmnMz #alzheimers #dementia
Join now to see what you are missing
Similar pages
- Phanes Therapeutics, Inc. Biotechnology Research San Diego, California
- QNu Labs Computer and Network Security Bengaluru, Karnataka
- VERAVAS, Inc. Medical and Diagnostic Laboratories Austin, TX
- Quadrant Technologies IT Services and IT Consulting Redmond, Washington
- Bullpen Industry Associations
- Access Airways Medical Equipment Manufacturing Blaine, Minnesota
- ChromaTan, Inc Biotechnology Research Ambler, PA
- Precision Neuroscience Medical Equipment Manufacturing Manhattan, NY
- Christiaan & Company Business Consulting and Services Minneapolis, Minnesota
- Riverleaf Biotech Industries, LLC Biotechnology Eugene, Oregon